English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Histone Modifiers in Cancer: Friends or Foes?

MPS-Authors
/persons/resource/persons191010

Cohen,  Idan
Spemann Laboratory, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

Kinga,  Kamieniarz
Max Planck Society;

/persons/resource/persons15783

Schneider,  Robert
Spemann Laboratory, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Cohen, I., Poreba, E., Kinga, K., & Schneider, R. (2011). Histone Modifiers in Cancer: Friends or Foes? Genes & Cancer, 2, 631-647.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002B-8DF5-9
Abstract
Covalent modifications of histones can regulate all DNA-dependent processes. In the last few years, it has become more and more evident that histone modifications are key players in the regulation of chromatin states and dynamics as well as in gene expression. Therefore, histone modifications and the enzymatic machineries that set them are crucial regulators that can control cellular proliferation, differentiation, plasticity, and malignancy processes. This review discusses the biology and biochemistry of covalent histone posttranslational modifications (PTMs) and evaluates the dual role of their modifiers in cancer: as oncogenes that can initiate and amplify tumorigenesis or as tumor suppressors.